Trends Immunol. 2025 May 13:S1471-4906(25)00120-6. doi: 10.1016/j.it.2025.04.007. Online ahead of print.
ABSTRACT
Recently, Kondo et al. engineered the coexpression of a T cell receptor (TCR) and a chimeric antigen receptor (CAR) and developed an antagonism-enforced braking system where TCR signals both enhance and inhibit CAR activation. This work may enable rational design of CAR-T agents that limit toxicity to healthy tissue.
PMID:40368698 | DOI:10.1016/j.it.2025.04.007